A Phase 2 Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein [Mucin 1-Glutathione S-Transferase] Coupled to Oxidized Polymannose) in Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Cancer vaccine MUC-1 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Immutep Limited
- 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
- 10 Jun 2017 Biomarkers information updated
- 02 Apr 2015 Status changed from discontinued to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.